These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 15367278)
1. What is the calcineurin inhibitor of choice for pediatric renal transplantation? Kari JA; Trompeter RS Pediatr Transplant; 2004 Oct; 8(5):437-44. PubMed ID: 15367278 [TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitors in renal transplantation: what is the best option? Tanabe K Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261 [TBL] [Abstract][Full Text] [Related]
5. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536 [TBL] [Abstract][Full Text] [Related]
7. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
9. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S; Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205 [TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Höcker B; Tönshoff B Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600 [TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Flechner SM; Kobashigawa J; Klintmalm G Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899 [TBL] [Abstract][Full Text] [Related]
12. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India. Agarwal SK; Bhowmik D; Mahajan S; Bagchi S Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825 [TBL] [Abstract][Full Text] [Related]
13. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910 [TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
15. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974 [TBL] [Abstract][Full Text] [Related]
16. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Kobashigawa JA; Miller LW; Russell SD; Ewald GA; Zucker MJ; Goldberg LR; Eisen HJ; Salm K; Tolzman D; Gao J; Fitzsimmons W; First R; Am J Transplant; 2006 Jun; 6(6):1377-86. PubMed ID: 16686761 [TBL] [Abstract][Full Text] [Related]
17. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169 [TBL] [Abstract][Full Text] [Related]
18. Controlling treatment allocation bias in a registry analysis when comparing calcineurin inhibitors. Bunnapradist S; Takemoto SK Transplant Proc; 2003 Nov; 35(7):2407-8. PubMed ID: 14611971 [TBL] [Abstract][Full Text] [Related]
19. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031 [TBL] [Abstract][Full Text] [Related]
20. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. Zhang X; Ji L; Yang L; Tang X; Qin W Int Urol Nephrol; 2016 May; 48(5):731-43. PubMed ID: 26781720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]